Ascletis Pharma’s ASC40 Meets Acne Treatment Goals in Phase II Trial
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its first-in-class, once-daily oral fatty acid...
BDgene Technology’s BD111 Receives Tacit Approval for HSV-1 Keratitis Trial
Shanghai BDgene Technology Co., Ltd has announced that it has received tacit clinical trial approval...
SanReno Therapeutics Completes Dosing in Kidney Disease Trial for BION-1301
SanReno Therapeutics, a China-based joint venture (JV) specializing in nephropathy treatments, has announced the completion...
Qilu Pharmaceutical Launches First Generic Iressa in the US Market
China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ,...
NeuExcell Therapeutics Secures Over $14.5 Million in Pre-Series A+ Funding for Neurological Treatments
NeuExcell Therapeutics, a Sino-US biotech company specializing in treatments for neurological damage and degenerative diseases,...
Transcenta’s Osemitamab Achieves Full Enrollment in Phase II Gastric Cancer Study
Transcenta Holding Limited (HKG: 6628), a China-based biopharmaceutical company, has announced the completion of enrollment...
TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases
Shanghai-based TYK Medicines has announced that it has received the green light from the Center...
NMPA Transitions Desloratadine, Loratadine, Ambroxol, and Naproxen to OTC Status
The National Medical Products Administration (NMPA) has indicated on its website that four products will...
Skyline Therapeutics Reports Positive Preclinical Results for SKG0106 and SKG0201 Gene Therapies
Skyline Therapeutics, a Shanghai-based cell and gene therapy (CGT) developer, has announced encouraging preclinical study...
Cellular Biomedicine Group Inc. and Janssen Biotech, Inc. Announce Global Collaboration for CAR-T Therapies
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG), emerging from a merger deal in...
Chinese Authorities Launch Special Campaign to Combat Fraud in Medical Insurance
The National Healthcare Security Administration, Supreme People’s Procurator, Ministry of Public Security, Ministry of Finance,...
Johnson & Johnson’s Kenvue IPO Raises USD 3.8 Billion, Marking Year’s Largest US IPO
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced the initial public offering...
Full-Life Technologies Ltd to Establish GMP-Compliant Radiopharmaceutical Plant in Belgium’s Wallonie Region
Shanghai-headquartered Full-Life Technologies Ltd has announced a significant land acquisition deal in the Wallonie region...
China’s CDE Unveils Technical Guidelines for Stem Cell Products and Immunotherapy in Chronic Hepatitis B
The Center for Drug Evaluation (CDE) has released a series of Technical Guidelines aimed at...
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over...
CMS Receives NMPA Approval for Clinical Study of Tetravalent BsAb for nAMD
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...
Sirnaomics’ RV-1730 Receives FDA Clearance for Phase I COVID-19 Vaccine Booster Trial
Sirnaomics Ltd (HKG: 2257) has announced that it has received clearance from the United States...
Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy
Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of...
Zai Lab Partners with MediLink Therapeutics to Develop YL212 DLL3 ADC
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688), a China-based biopharmaceutical company, has announced a strategic...
Jiangsu Hengrui’s Vunakizumab for Plaque Psoriasis Accepted for Review by NMPA
Jiangsu Hengrui Pharmaceutials Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, announced that the...